Annual Report 2009

Active Biotech

Annual Report

2009

Annual Report 2009

Contents

Active Biotech in brief 3

Comments from the CEO 4

Directors’ report 6

T H E G R O U P

Income statement 13

Cash-flow statement 13

Comprehensive income 13

Financial position 13

Changes in shareholders’ equity 14 T H E PA R E N T CO M PA N Y

Income statement 14

Cash-flow statement 14

Balance sheet 15

Changes in shareholders’ equity 15 Notes to the financial reports 16

Audit report 37

Financial development 38

The share 39

Intellectual property rights 42

Corporate Governance Report 2009 43 Board of Directors and Auditors 46

Management Group 47

Glossary 48

Business concept, goals and

business strategy 48

Financial information

Interim report (Q1) April 22, 2010 Annual General Meeting May 6, 2010

Interim report (Q2) Aug 11, 2010

Interim report (Q3) Oct 27, 2010

Year-end report for 2010 Feb 10, 2011 Financial information can be requested from Active Biotech AB, PO Box 724, SE-220 07 Lund, Sweden. Telephone +46 (0)46-19 20 00, fax +46 (0)46-19 11 00.

Information can also be obtained from our website www.activebiotech.com.

This Annual Report contains forward-looking information regarding Active Biotech. Although we believe that our expectations are based on reasonable assumptions, forward-looking state- ments could be affected by factors causing the actual outcome and trend to differ materially from the forecast. The forward-looking statements comprise various risks and uncertainties. There are significant factors that could cause the actual outcome to differ from that implied by these for- ward-looking statements, some of which are beyond our control. These include the risk that patent rights might expire or be lost, exchange-rate movements, the risk that research and development operations do not result in commercially successful new products, competition effects, tax risks, effects resulting from the failure of a third party to deliver products or services, difficulties in obtaining and maintaining official approval for products, and environmental responsibility risks.

Annual General Meeting

The Annual General Meeting of Active Biotech AB (publ) is to be held on Thursday, May 6, 2010 at 5:00 p.m. at the company’s premises at Scheelevägen 22 in Lund, Sweden. Shareholders who wish to participate in the Meeting must (a) be recorded in the register of shareholders maintained by Euroclear Sweden AB (formerly VPC AB) on Thursday, April 29, 2010 and (b), notify the company of their intention to participate in the Meeting not later than 4:00 p.m. on Thursday, April 29, 2010.

Shareholders who have trustee-registered shares must temporarily re-register the shares in their own name with Euroclear Sweden to be entitled to participate in the Meeting. This registration must be completed not later than Thursday, April 29, 2010. Accordingly, shareholders must inform the trustee of this request in ample time prior to this date.

Notice of participation

Notice of participation can be made in writing to Active Biotech AB (publ), Attn. Susanne Jönsson, PO Box 724, SE-220 07 Lund, Sweden, by fax +46 (0)46-19 20 50, by telephone to +46 (0)46-19 20 00 or by e-mail to susanne.jonsson@activebiotech.com. The notice shall include name, personal/corporate registration number, number of shares held, daytime telephone number and, if applicable, the number of advisors (two at the most) that will accompany the shareholder at the Meeting.

The notice of the Annual General Meeting is available in its

entirety on the company’s website www.activebiotech.com.

Active Biotech in brief

MS

Laquinimod Crohn’s

Lupus

Autoimmunity/inflammation Cancer Striped = Ongoing

ANYARA Renal cell cancer

TASQ Prostate cancer

RhuDex^TM RA

57-57 SLE

ISI

DISCOVERY PHASE

PRIMARY INDICATION PRECLINICAL DEV.

PROJECT CLINICAL PHASE I CLINICAL PHASE IICLINICAL PHASE III PARTNER

Selection of candidate drug (CD) ACTIVE BIOTECH IN BRIEF

Active Biotech currently has five projects in clinical phase, two of which are out- licensed. Three of the projects relate to drugs for the treatment of the autoimmune diseases MS, SLE and RA, and two of the projects focus on drugs for the treatment of cancer, mainly renal cell cancer and prostate cancer. In addition, Active Biotech pursues a preclinical project, ISI.

n Laquinimod is a compound under development for the treatment of autoimmune diseases, including MS. Compared with existing treatment alternatives, laquinimod has the advantage of being orally administered. Active Biotech

has signed an agreement with the Israeli pharmaceutical company Teva for the development and commercialization of laquinimod. Clinical Phase III trials are currently under way and include more than 2,000 patients. In February 2009, fast-track status was granted by the US Food and Drug Administration, FDA, which means that laquinimod may be launched in the US in 2011.

n With the TASQ project, Active Biotech is developing an antiangiogenic com- pound that attacks the tumor’s growth by inhibiting the formation of blood vessels in the tumor. The development of TASQ is mainly focused on the treatment of prostate cancer. In December 2009, the first results were presented

from the ongoing Phase II trial with slightly more than 200 patients. The primary endpoint – to show a higher fraction of patients with no disease progression

following a six-month period of treatment with TASQ – was achieved. Planning for pivotal Phase III trials is under way.

n ANYARA is a protein drug that makes the treatment of cancer tumor-specific. The development of ANYARA is primarily focused on renal cell cancer, but the compound has also demonstrated favorable results in connection with the treatment of, for example, non-small cell lung cancer. The compound is currently undergoing pivotal Phase III trials encompassing just over 500 renal cell cancer patients. The results from the study are expected to be presented during the first half of 2011.

n 57-57 is a compound for treatment of SLE, a disease that causes inflammation and damage to the connective tissue of many organs in the body with serious secondary symptoms, such as renal failure. Phase I clinical trials were concluded in 2008. In 2009, an explorative clinical study that will include up to 20 SLE patients in Sweden and Denmark was initiated. The aim of the trial is to study

how the parameters that correlate with disease activity are affected by the treatment.

n ISI is a project that was launched in 2008. The aim of the project is to utilize the company’s own preclinical results that were generated around a target molecule, S100A9, for the quinoline compounds and their biological mode of action. The objective of the project it to produce new, patentable chemi- cal compounds that interact with S100A9. The selection of a candidate drug is expected to take place in 2011.

n RhuDex^TM is a compound that is primarily intended to be used as a drug for the treatment of RA. Active Biotech has entered into a licensing agreement with the German pharmaceutical company MediGene AG, which grants MediGene the exclusive right to further develop and market the product.

Phase II clinical trials were concluded in 2008. In December 2009, MediGene announced that further preclinical studies were to be conducted in 2010 to optimize the continued clinical development program. Clinical trials are expected to be resumed at the end of 2010 or beginning of 2011.

4

COMMENTS FROM THE CEO

Active Biotech had a highly successful year and this should be a source of gratification to us all. At the same time, I would like to emphasize that it is the long-term approach and perseverance of our shareholders that is now yielding results in the form of an appreciation in the value of the company after nearly a decade. This appreciation in value is based on successes in our projects.

It is also important to keep mind that the aim of our work is to provide improved treatment alternatives for pa- tients affected by serious diseases. If we achieve this goal, the company’s value will continue to increase accordingly.

The year 2009 was a very positive 12 months for Active Biotech’s shareholders. On the last trading day in 2008, the share was valued at SEK 31.00, while the same share was valued at SEK 100.75 one year later. Since the company implemented a rights issue in 2009, it is more relevant to compare the company’s market capitalization on both of these dates. With such an analysis at hand, we can see that the company had a total value of about SEK 1.6 billion at the end of 2008 – and about SEK 6.5 billion at the close of 2009.

Active Biotech’s market capitalization has thus increased in value by 306 percent. At a time such as this, it is important to take a step back and reflect on what is company-specific and what is governed by the external environment; I will come back to the company’s project-related events below.

We can start by noting that the Stockholm general index rose 47 percent during the period, with its biotech index recording an 88-percent rise. It is also worth noting that the value of the share at the beginning of the year was depressed due to the ongoing financial crisis and a generally turbulent financial market. Finally, we can see that at the end of 2009, the company’s value was the highest since its foundation, with the previous highest value noted in 2000 (about SEK 4.2 billion).

Focus on the company’s financing

Active Biotech remains a loss-making company. According to current plans, the company will continue in this manner until 2011/2012. The primary focus for management and the Board must therefore be to ensure the company’s financing.

Consequently, the approval of a renewed mandate authorizing the Board to issue new shares will be requested at the AGM.

In 2009, we implemented a rights issue which generated SEK 249 million in net proceeds for the company. Leasing of premises and commissioned research work also yielded revenues of nearly SEK 11 million. At the beginning of April 2010, Active Biotech raised a further SEK 149 million through a directed share issue placed in funds managed by Sectoral Asset Management. As a result, the company has secured financing for the period until the first half of 2011.

According to plan, we are expecting to receive revenues in

2010/11 from the out-licensing of the TASQ project and nonrecurring payments linked to the laquinimod agreement.

Based on this scenario, Active Biotech currently has no plans for additional financing activities.

Laquinimod proceeding according to plan

Our lead project, laquinimod, is proceeding according to plan. In June 2009, together with our partners Teva, we announced that a second Phase III trial (“Bravo”) for the treatment of multiple sclerosis (MS) was fully enrolled. This means that more than 2,000 patients are now participating in pivotal studies for this indication. The patients will be treated over a period of two years after which laquinimod’s effect on disease progression will be determined. At the end of 2010, treatment of the final patient in the first Phase III study (“Allegro”) will be complete. We can thus look forward to receiving final data with respect to laquinimod’s effect on MS.

Teva also initiated clinical Phase II trials for the treatment of Crohn’s disease with laquinimod and is also planning to initiate Phase II trials for the treatment of lupus nephritis and systemic lupus erythematosus (SLE) prior to summer 2010 (www.clinicaltrials.gov). All of these diseases are chronic, inflammatory diseases with an underlying autoimmune component. Active Biotech takes a very positive view of this development, since these increased investments in laquinimod could generate additional royalty revenues for the company in the long term, while Teva bears the entire cost of deve- lopment. We look forward to following the progression of these clinical programs.

Fast-track status for laquinimod

Another important event during the year was the Active Biotech and Teva announcement that laquinimod has been granted fast-track status by the FDA. This will facilitate and thus accelerate the future registration process for laquinimod.

In the same press release, it was mentioned that laquinimod could be available in the market as early as at the end of 2011.

Finally, it can be noted that Teva published positive results during the year from the follow-up study of the earlier Phase II trial of laquinimod. A sustained effect on MS could be observed following nine months of treatment and the highly

An exceptional year

5

COMMENTS FROM THE CEO

favorable safety profile was retained. Several preclinical trials were also published that show that laquinimod confers both neuroprotective and anti-inflammatory properties.

New partnership agreement with Teva

In February 2010, Active Biotech and Teva announced that Teva had acquired the marketing and distributions rights for laquinimod in Active Biotech’s territory. I am very pleased with this agreement for two reasons. Firstly, the royalties the company will receive in the Nordic/Baltic countries are very attractive and, secondly, it is my under- standing that Teva will be a very efficient partner for sales in our territory. Furthermore, Active Biotech will avoid further increasing its costs to build up a sales organization.

57-57 – Exploratory study in progress

In February 2009, Active Biotech announced that the planned Phase II/III trial to be conducted by the company for the treatment of Systemic Lupus Erythematosus (SLE) within the 57-57 project would not go ahead. The reason for this decision was not based on scientific or medical arguments but on the necessity to limit the financial risk in the company.

We initiated a small-scale, explorative study to further validate some of the effects on various biomarkers that were observed in the concluded Phase I study. This explorative study will be completed in 2010. Our partner Teva’s growing interest in lupus-related indications means that Active Biotech will undertake a strategic review of the 57-57 project in 2010 to identify a maximum synergy with Teva’s development program for laquinimod. I expect to announce a definite decision on our plans before the end of the year.

Approval for RhuDex

– Continued significant potential against RA

The development of RhuDex is pursued by our partner MediGene. MediGene has concluded a Phase IIa trial and prepared a Proof of Concept Phase IIb trial for the treatment of rheumatoid arthritis (RA).

In 2008, a death unfortunately occurred in a Phase I trial during treatment with RhuDex in healthy volunteers. This death has been considered by MediGene to be unrelated to the compound, but following consultation with the con- cerned regulatory authority, a decision was made to compile supplementary documentation of the safety of RhuDex.

In October 2009, MediGene announced that it had success- fully concluded this supplementary preclinical documentation and was subsequently granted approval by the regulatory authority to continue the clinical development program.

MediGene is planning to perform further preclinical studies on a proprietary basis in 2010, to then initiate new Phase II trials at the end of 2010 or beginning of 2011. The belief is still that RhuDex has significant potential to be an important therapy alternative for patients affected by RA.

ANYARA proceeding according to plan

The ANYARA project, for the treatment of renal cancer, proceeded according to plan during the year. In June 2009, we could announce that the ongoing Phase III trial was fully enrolled, meaning that more than 500 patients are included in the study. The primary endpoint of this study is overall survival. This means that the length of the trial will not have a set endpoint, but will be governed by events. Consequently, we cannot determine when it will be concluded, but my current assessment is that we will see results during first half of 2011. In 2009, Phase I results were also published for ANYARA from patients with renal cell cancer, pancreatic cancer and lung cancer in a scientific journal (Journal of Clinical Oncology).

TASQ reached the primary endpoint

For TASQ, Active Biotech’s project for the treatment of prostate cancer, a Phase II clinical trial was fully enrolled in June 2009. Complete Phase I results were also published in a scientific journal (British Journal of Cancer). In the Phase II study, patients with metastasized, hormone-resistant prostate cancer are treated with either 1 mg/day TASQ or placebo over a period of six months. The primary endpoint was, through treatment with TASQ, to increase the proportion of patients who did not display disease progression.

Disease progression includes increase in the size of the tumor, new metastases or serious pain that requires treatment with cytotoxins, radiation and or morphine. In December 2009, we were able to announce that the primary endpoint had been reached with high statistical significance. This means that we can now plan for the further clinical deve- lopment of TASQ. In parallel with this activity, we will initiate discussions with potential partners for the project, which represents the greatest commercial challenge for the company in 2010.

Thank you for an exceptional year

In conclusion I can say that 2009 was an exceptional year for Active Biotech and for our projects. We have fully enrolled three major clinical trials, achieved proof of concept for the second time in the company’s history, and published a first target molecule for quinolines. It only remains for me to extend my gratitude to all employees who, with a high degree of expertise and loyalty, help to advance this complicated business forward; and all shareholders whose confidence in Active Biotech allows us to develop new drugs.

Lund, Sweden April 2010

Tomas Leanderson, President and CEO

6

The Board of Directors and President & CEO of Active Biotech AB (publ), Swedish corporate registration number 556223-9227, hereby submit their Annual Report and consolidated financial statements for the fiscal year January 1, 2009 to December 31, 2009. Active Biotech conducts operations as a limited liability company and has its registered office in Lund, Sweden.

Operations

Active Biotech is a company that focuses on pharmaceutical research and development in medical fields in which the immune system plays a central role. The company’s research portfolio primarily includes projects for the development of drugs for the treatment of autoimmune/ inflammatory diseases and cancer.

The Group

The Group’s legal structure is built around the Parent Company Active Biotech AB, which comprises Group-wide functions and asset management, as well as the wholly owned subsidiary Active Biotech Research AB, which conducts pharmaceutical research in Lund, and Active Forskaren 1 KB in Lund, which owns the property in which Active Biotech conducts operations.

Active Biotech’s research operations

Active Biotech’s field of expertise mainly comprises the human immune system. This knowledge is used to develop drugs for the treatment of autoimmune/inflammatory diseases and cancer.

The company currently has five projects in clinical development. Three of these projects involve the develop- ment of potential drugs intended for the treatment of autoimmune/ inflammatory diseases. The projects address the indications multiple sclerosis, MS (laquinimod), systemic lupus erythematosus, SLE (57-57) and rheumatoid arthritis, RA (RhuDex

). The project portfolio also includes two potential drugs for treatment of the indications renal cell cancer (ANYARA) and prostate cancer (TASQ). In addition to these five clinical projects, the company pursues one preclinical project, called ISI, aimed at exploring the company’s own preclinical results generated around a target molecule for quinoline (Q) compounds and their biological mode of action. The project aims at producing new, patentable chemical substances that interact with the target molecule of the Q compounds.

In general, research operations performed very favorably in 2009.

Progress in brief for each project Laquinimod

Laquinimod is the project that has progressed furthest in the clinical development process. It is a new, immunomodulatory, disease-modifying oral drug for the treatment of MS.

Following the completion of Phase I and Phase II trials by Active Biotech on a proprietary basis, an agreement was signed with Teva Pharmaceutical Industries Ltd (Teva) in June 2004 covering the development and commercialization

of laquinimod. According to the agreement, Teva performs and funds the continued clinical development of laquinimod.

If all the milestones in the clinical development are achieved, Teva will pay USD 92 million to Active Biotech, USD 17 million of which has been received to date. Active Biotech will also receive tiered double-digit royalty payments on future sales. The agreement grants Teva the exclusive rights to develop, register, produce and commercialize laquinimod globally, with the exception of the Nordic and Baltic countries, where Active Biotech retains all commercial rights.*

In September 2006, Teva successfully concluded an additional Phase II trial ahead of pivotal Phase III trials.

The aim was to further evaluate the safety and efficacy of laquinimod and to establish the clinical dose for Phase III trials.

In the latter part of 2007, the clinical Phase III study Allegro (assessment of oral laquinimod in preventing progression of multiple sclerosis) commenced, which is a global, pivotal, 24/30-month, double-blind trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo in the treatment of relapsing-remitting multiple sclerosis (RRMS). In November 2008, Teva announced that the study, comprising 1,000 patients, was fully enrolled.

Efficacy, safety and tolerability in laquinimod are also being studied in a second Phase III study focused on RRMS, Bravo (benefit-risk assessment of Avonex

and laquinimod). The Bravo trial is a global, multi-center, randomized, placebo- controlled trial with parallel groups, in which the effects of laquinimod are compared with placebo. The study will also generate data that assesses the risk and benefits with once-daily administered laquinimod compared with an injectable product presently established in the market (Avonex

). In June 2009, Teva announced that the Bravo study was fully enrolled, which means that the study encompasses about 1,200 patients that will be monitored for a period of 24 months.

In February 2009, Teva received a fast-track status from the US Food and Drug Administration, FDA, for laquinimod, which could facilitate the development and accelerate the registration process. This may mean that laquinimod will be available in the market as early as the end of 2011. In September 2009, new data was presented that demonstrates that laquinimod displays both neuroprotective and anti- inflammatory properties.

Teva also announced that the company initiated a Phase II program for laquinimod in Crohn’s disease and Lupus.

* In February 2010, Active Biotech announced that Teva had acquired the commercial rights for laquinimod in the Nordic and Baltic regions. The agreement means that Active Biotech will significantly higher royalty rate on future sales in the Nordic and Baltic regions that the royalty rate set for the rest of the world.

TASQ

In the TASQ (Tumor Angiogenesis Suppression by Quino- lines) project, Active Biotech is developing an antiangiogenic substance that attacks the tumor’s growth through inhibition of the formation of blood vessels in the tumor. TASQ can be administered orally for the treatment of prostate cancer.

Directors’ report

DIRECTORS’ REPORT

7

An initial clinical Phase I trial involving healthy volunteers was concluded in February 2004. In November 2004, the clinical Phase I dose-escalation program with prostate cancer patients commenced, with the purpose of studying the safety of TASQ. The study comprised a total of 32 patients with hormone-refractory prostate cancer. TASQ was well tolerated by all patients with only mild and transient side effects.

Patients continued treatment in a follow-up study that aimed to document long-term tolerance and safety.

The US Food and Drug Administration’s review of the IND (Investigational New Drug) application was completed in August 2007. A Phase II proof of concept study was ini- tiated during the latter part of the year. This is a randomized, placebo-controlled, double-blind Phase II study of 1 mg/

day of TASQ versus placebo in just over 200 patients. The study comprises symptom-free patients with metastatic, hormone-resistant, prostate cancer. The primary endpoint of the study is to measure the proportion of patients that do not display disease progression after six months of TASQ therapy compared with placebo. Secondary clinical endpoints of importance for this group of patients include time to clinical progression and initiation of treatment with cytostatics.

In September 2009, the results from the Phase I trial were published in the British Journal of Cancer. The results showed that long-term continuous oral administration of TASQ seems to be safe and that TASQ might delay disease progression.

It was announced in December 2009 that the primary endpoint of the Phase II clinical study, to show a lower fraction of patients with disease progression during the six-month period of treatment using TASQ, had been reached. The percentage of patients with disease progression during the six-month period was 43 percent for patients treated with TASQ compared with 67 percent for placebo-treated patients.

TASQ treatment also had a positive effect on several biomar- kers relevant for prostate cancer progression and was generally well tolerated. Complete results from the trial will be presented in 2010 at a scientific conference and in scientific journals.

ANYARA

In the ANYARA project, Active Biotech is developing an immunological targeted treatment of cancer that stimulates the immune system to eradicate tumor cells. Following the optimization of the first-generation candidate drug, the ANYARA project now comprises a compound that is designed to provide an improved anti-tumor effect and lower toxicity, which can therefore be administered at significantly higher doses. In 2006, three clinical Phase I studies of ANYARA for the treatment of advanced non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and pancreatic cancer (PC) were successfully concluded. The median survival of 26.2 months observed for patients with advanced renal cell cancer and treated with ANYARA is twice the expected length.

In July 2007, ANYARA was granted Orphan Drug Status for the treatment of renal cell cancer patients by the EMEA’s (European Medicines Agency) expert committee. The EMEA’s decision to grant Orphan Drug Status was an important step in the development of ANYARA and provides a variety

of incentives, including market exclusivity for up to ten years following registration approval.

A combined Phase II/III trial for the treatment of renal cell cancer was initiated prior to year-end 2006 at about 50 clinics in Europe. The trial is a randomized study of ANYARA in combination with interferon-alpha, compared with only interferon-alpha, in patients with advanced renal cell cancer.

The primary endpoint for this study is extended overall survival and the trial includes just over 500 patients. In May 2008, following the enrolment of approximately 250 patients in the trial, an interim analysis was conducted with positive results. In July 2009, the results from two Phase I studies of ANYARA were published in the Journal of Clinical On- cology, where ANYARA was studied both as a single agent (monotherapy) and in combination with an established tumor therapy – docetaxel (Taxotere

). The results showed that ANYARA was well tolerated both as monotherapy and in combination with docetaxel. The ongoing, pivotal, Phase II/III trial of ANYARA is fully enrolled since June 2009 and in proceeding as planned. The length of the trial will depend on disease progression in patients and a report is expected to be presented during the first six months of 2011.

57-57

In the company’s 57-57 project, Active Biotech is developing an immunomodulatory compound primarily for the treatment of systemic lupus erythematosus (SLE), a disease that causes inflammation and damage to the connective tissue of many organs in the body with serious secondary symptoms, such as renal failure.

The first clinical Phase I dose-escalation study, comprising 30 healthy volunteers, was started at the Karolinska University Hospital in Stockholm in November 2004 and was success- fully completed in July 2005. The results showed that 57-57 is very well tolerated at all of the tested dosage levels in single and multiple doses and that the compound is suitable to be administered as an oral, daily treatment. The clinical devel- opment program continued with a Phase Ib trial of SLE patients, which commenced in December 2005. The study primarily documented safety and pharmacokinetic properties, but also monitored a number of biological markers to deter- mine the effect of 57-57 on disease progression. The study was concluded in 2008 and data from the trial confirmed the previously exhibited favorable safety profile, and dem- onstrates effects on markers for the SLE disease. During 2008 and 2009, follow-up data from the concluded Phase Ib trial was presented at scientific conferences. The results show that by treating patients with 57-57, it is possible to affect signaling pathways that are essential for the progression of SLE. At the beginning of 2009, an announcement was made that the continued clinical development of 57-57 on a proprietary basis would be discontinued and that activities to out-license 57-57 had been initiated. In 2009, an ex- ploratory clinical study was initiated that will include up to 20 patients in Sweden and Denmark. The aim of the study is to examine several parameters that correlate with the disease activity.

DIRECTORS’ REPORT

8

RhuDex

RhuDex is a orally active compound for the treatment of rheumatoid arthritis (RA), originating from Active Biotech’s patented CD80 antagonists, out-licensed in 2002 to Medi- Gene AG’s (MediGene) subsidiary Avidex Ltd. Following successful preclinical development work, a candidate drug was selected in 2004 under the name of RhuDex, an orally administered small molecule primarily intended for the treat- ment of RA. Phase I studies of RhuDex commenced during the spring of 2005, which entailed a small milestone payment to Active Biotech and in March 2006, the company could report that RhuDex had successfully concluded two Phase I studies in which safety, tolerability and pharmacokinetic properties had been studied in healthy volunteers. A Phase IIa dose-escalation study in 35 RA patients was initiated in early 2007 and in June 2008, it was announced that the clinical trial had achieved its endpoint. Following approval in October 2009 to continue the clinical development, MediGene announced that further preclinical studies were to be con- ducted in 2010 to optimize the clinical program. Clinical trials are expected to be resumed at the end of 2010 or beginning of 2011.

MediGene is responsible for the development and carries the related costs of the clinical program. If the project continues to market launch, milestone revenues could total GBP 5.8 million. In addition, Active Biotech will receive royalties on future sales.

ISI-projektet

Active Biotech’s ISI project was initiated in the second quarter of 2008. Previous work has shown that quinoline compounds will inhibit the interaction between a defined target, S100A9, and at least two endogenous, pro-inflammatory receptors.

An in-house library and commercially available libraries of compounds have been screened for binding to the target molecule using a surface plasmon resonance assay (Biacore).

Hits have been defined from two different, non-quinoline chemical classes that are currently being refined. The objective of the ISI project is to define new, patentable target-binding small molecule compounds with superior pharmacological properties compared to the existing quinolines. In 2009, a lead substance has been chosen for further preclinical optimization.

The target for filing of new patents and selection of a first candidate drug is 2011.

Comments on the income statement

The Group’s net sales amounted to SEK 10.8 million (53.5) and comprised service and rental revenues of SEK 10.8 million (10.6). The corresponding period in the preceding year in- cluded a milestone payment from Teva totaling SEK 41.2 million and a research grant from Vinnova of SEK 1.7 million.

Research and administrative costs amounted to SEK 230.3 million (238.1), corresponding to a 3-percent decrease in costs. Research and development costs increased by SEK 4.6 million from SEK 207.4 million to SEK 212.0 million. The increase in costs is attributable to intensified clinical research activities and more extensive trials in later clinical phases,

particularly the ongoing Phase II/III study for the ANYARA project, and the Phase II study for the TASQ project. Admin- istrative expenses decreased from SEK 30.7 million to SEK 18.3 million as a result of the change of CEO in 2008, which had full effect in 2009. The cost outcome in 2009 was nega- tively impacted by the weakening of the Swedish krona, since about 37 percent of research expenses comprise research services purchased abroad, mainly within the areas of clinical development and manufacture of clinical material.

At year-end, the clinical development program comprised a total of five projects, of which laquinimod and RhuDex are financed by partners and the three other projects ANYARA, TASQ and 57-57 are financed by Active Biotech. In addition to the clinical development program, the company also pursues the preclinical research project ISI, the aim of which is to utilize the Active Biotech’s own preclinical results that were generated around a target molecule for the quinoline compounds and their biological mode of action.

The consolidated operating loss amounted to SEK 219.6 (loss: 184.6). The deterioration in earnings is attributable to reduced revenues, since earnings in 2008 included a milestone payment from Teva totaling SEK 41.2 million.

Consolidated net financial items amounted to an expense of SEK 4.4 million (income: 4.0). The development in net financial items was mainly due to the inclusion in 2008 earn- ings of a capital gain totaling SEK 7.4 million recognized in connection with the divestment of the minority shareholding in the UK research company Isogenica Ltd. Interest income amounted to SEK 6.3 million (10.2) and interest expenses totaled SEK 10.7 million (6.2), of which SEK 3.5 million relates to the market valuation of interest-rate swaps entered into in 2009. The interest-rate swaps are revalued continuously and had no impact on cash flow in 2009. The Group’s loss after tax amounted to SEK 224.0 million (loss: 181.6).

Comments on the balance sheet

The Group’s total assets amounted to SEK 498.5 million (472.9), of which tangible fixed assets amounted to SEK 319.0 million (324.6) and comprised the property in which the company conducts operations, amounting to SEK 309.4 million (316.6), and equipment, tools, fixtures and fittings totaling SEK 9.6 million (8.0). At year-end, cash and cash equivalents totaled SEK 156.0 million (138.7).

Comments on the cash-flow statement

The Group’s positive cash flow for full-year 2009 amounted to SEK 17.3 million (0.1). The negative cash flow from operating activities amounted to SEK 224.8 million (neg:

159.5). Cash flow from investing activities amounted to a negative SEK 0.1 million (pos: 7.0) and the cash flow from financing activities amounted to SEK 242.1 million (152.6).

Investments in tangible fixed assets amounted to SEK 4.0 million (6.3), of which SEK 3.9 million (3.5) was financed through financial leasing agreements.

DIRECTORS’ REPORT

9

Cash and cash equivalents and financial position At year-end, cash and cash equivalents amounted to SEK 156.0 million (138.7). A rights issue was implemented in 2009, providing the company with a capital infusion of SEK 249.0 million after issue expenses. The Board of Active Biotech has established a policy for the investment of the Group’s cash and cash equivalents, which stipulates that these be invested at low credit risk, primarily in short-term Swedish securities, commercial papers and fixed-income and bond funds with high liquidity. Interest-bearing liabilities amounted to SEK 255.5 million (258.4), of which SEK 246.7 million (251.9) is represented by a property loan and SEK 8.8 million (6.5) by liabilities to leasing companies. At year-end, consolidated shareholders’ equity amounted to SEK 188.6 million (163.6).

The Group’s equity/assets ratio was 37.8 percent at year-end 2009, compared with 34.6 percent at year-end 2008.

The Active Biotech share

Share capital and ownership structure

In February 2010, following the exercise of employees stock options, Active Biotech AB’s share capital amounted to SEK 241.7 million distributed among 64,120,760 shares. The company has one class of share. All shares carry equal rights to participation in the company’s assets and dividends. For further information regarding shareholders, see page 41.

Corporate governance

Active Biotech AB’s Articles of Association stipulate that the election of the Board shall always take place at the Annual General Meeting. Apart from this, the Articles of Association do not contain any stipulations governing how Board members are appointed or dismissed, or regarding changes to the Articles of Association.

A shareholder can vote for the full number of shares he or she holds or represents at General Meetings of Active Biotech. Shares that have been issued are freely transferable without restrictions pursuant to legislation or Active Biotech’s Articles of Association. The company is not aware of any agreements among shareholders that can entail restrictions on the entitlement to transfer shares in the company. For a more detailed description of how Active Biotech manages corporate governance issues, refer to the Corporate Governance Report on pages 43–45.

Parent Company

The operations of the Parent Company Active Biotech AB comprise Group-coordinative administrative functions. The Parent Company’s net sales for the year amounted to SEK 3.5 million (46.4). Operating expenses for the year amounted to SEK 22.2 million (expense: 33.2). Net financial income for the period amounted to SEK 2.3 million (50.5), with the difference between the years mainly attributable to a share in profits from subsidiaries and the divestment of the minority shareholding in the UK company Isogenica Ltd.

Only marginal investments were made during the period.

At year-end, the Parent Company’s cash and cash equivalents, including short-term investments, amounted to SEK 144.2 million, compared with SEK 131.6 million at the beginning of the year.

Risk factors

A research company such as Active Biotech is characterized by a high operational and financial risk, since the projects in which the company is involved are at the clinical phase, and there are a number of factors that have an impact on the likelihood of commercial success. The earlier in the develop- ment chain the project is, the higher the risk, while the risk decreases and the likelihood of reaching the market increases as each project completes the various specified development phases. The risk level of projects must be weighed against the potential that the projects will result in the development of a drug in the major indication areas addressed by the company. Active Biotech specializes in the development of pharmaceuticals. However, none of the company’s products have yet been approved for sale, and operations to date have therefore been loss-making. The Active Biotech projects that have advanced the furthest in terms of development into a finished drug entered Phase III trials in 2007, which means it could take until 2011 before any of these products are registered and approved for sale. As a result, Active Biotech will continue to recognize operating losses for several years to come, and there is a risk that the company may never report a profit.

Risks in operations

Although preclinical and clinical studies conducted for Active Biotech’s candidate drugs to date have produced positive out- comes, there are no guarantees that the continued requisite clinical studies will produce results that are sufficiently positive to secure approval. Neither are there any guarantees that the company will find necessary partners or that these partnerships will achieve the planned outcome. If approval is obtained, there is no guarantee that the approved product will achieve sales success. Competing products with better properties can be launched in the market or the company may prove inca- pable of marketing its product, either by itself or via partners.

While Active Biotech is constantly working to improve patent protection for its compounds, methods and applications, there is no guarantee that the patents will in fact provide the necessary protection or that competitors will not somehow circumvent the patents or in some other manner use the research findings or other intellectual rights that the company has built up. Both the extent and timing of the Group’s future capital requirements will depend on a number of factors, such as possibilities to enter into partnership agreements and the degree of success for development projects.

Official requirements

Active Biotech currently holds all the permits required to conduct its operations. Operations are naturally conducted in accordance with applicable legislation, and also meet high environmental and ethical standards. However, there is no guarantee that new requirements introduced by authorities will not make it more difficult to conduct operations.

Neither is there any guarantee that the currently applicable permits will be renewed on the same terms or that the company’s insurance cover, which is deemed adequate today, will prove adequate.

DIRECTORS’ REPORT

10

Financial risks

The Group has a currency exposure since operations are conducted in Sweden and research services are purchased internationally. Earnings are exposed to exchange-rate fluctuations with regard to the procurement of clinical trial services, research services and production of clinical materials.

Operating costs amounted to SEK 230.3 million during the fiscal year, of which about 37 percent corresponded to costs in foreign currencies. The proportion of costs in foreign currencies, principally in USD and EUR, may fluctuate as projects enter later phases of clinical development with more clinical studies potentially being conducted abroad.

Since the Group does not make use of forward contracts or options to hedge foreign-exchange risk, exchange-rate effects may impact the income statement. The company’s credit risks are marginal, since its operations are only subject to low invoicing levels by virtue of the fact that it currently engages primarily in research and development. For further information on financial risks, see Note 16 on pages 33-34.

The organization

At year-end, the number of employees in the Group amounted to 89 (90), of whom 52 (51) were women. The average age of employees was 49 (48) with an average employment period of 17.9 years (16.8). The education level of the personnel is high;

26 hold a PhD and 47 have university/college education.

During the year, the Group incurred average education costs of SEK 9,402 per employee. The number of employees in research and development was 74 (74). Sickness absence during the year amounted to 1.6 percent (1.0). The number of report- ed work injuries (including travel accidents) totaled 2 (3).

Incentive programs

An Extraordinary General Meeting on December 8, 2003 resolved to implement a free employee stock options program comprising a total of 1.0 million shares for all employees of the Active Biotech Group. The options program, combined with the hedging of future social-security costs and following the expiry of the series 1 options, comprises a total of 778,685 options, entailing a maximum dilution for existing shareholders of 1.5 percent. The incentive program is described in greater detail under the section “The share” on page 39 and in Note 5.

Environmental information

Active Biotech conducts its operations in accordance with the permits issued by the authorities for the company. The company has, for example, a permit from the Swedish Radiation Protection Institute for the handling of radioactive materials, and from the Swedish Board of Agriculture and the Swedish Work Environment Authority regarding genetically modified organisms.

In accordance with the Swedish Environmental Code, the company has registered its operations with the County Administrative Board. Inspections by the Swedish Work Environment Authority, the Lund Municipal Environmental Administration and the Swedish Radiation Protection

Institute all achieved satisfactory results. Active Biotech has a well-developed program for the sorting of waste at source and for the destruction of environmentally hazardous waste, and works actively to minimize energy consumption and the use of environmentally hazardous substances. Active Biotech is not involved in any environmental disputes.

Proposed appropriation of earnings

The Board of Directors and the President & CEO propose that no dividend be paid for the 2009 fiscal year. The proposed treatment of the company’s loss is detailed on page 12.

Report on the work of the Board

The Board decides on the Group’s overall strategy, the Group’s organization and management in accordance with the Swedish Companies Act. At year-end, the Board comprised five members elected by the Annual General Meeting, two employee representatives and two deputy employee representatives. Other white-collar employees in the company participate in Board meetings in a reporting capacity or in administrative functions. During the year, nine meetings were held at which minutes were taken. The President & CEO continuously informed the Chairman of the Board and the other Board members of developments in the company.

Important issues addressed by the Board included:

n

Development of research projects

n

Business development projects

n

Strategic focus

n

Information concerning financial statements

n

Budgets and forecasts for the operation

n

Partnership strategy and partnership discussions

The work of the Board and how Active Biotech is governed is described in detail in the “Corporate Governance Report”

section on pages 43-45. With regard to the Group’s and Parent Company’s results and financial position, reference is made to the subsequent income statements and balance sheets with the accompanying notes to the financial statements.

The Board’s proposed guidelines for remuneration of senior executives

The Board proposes that the Annual General Meeting to be held on May 6, 2010 decides on the following guidelines for remuneration of senior executives. These guidelines essentially conform to those that have been applied to date within the company. Senior executives are defined as the President & CEO and other members of Group management.

The guidelines shall apply to employment contracts entered into subsequent to the Board’s decision on guidelines and in those instances amendments are made in existing terms and conditions following the Board’s decision. Active Biotech shall offer total remuneration on market terms, facilitating the recruitment and retention of competent senior executives.

Remuneration to senior executives may comprise fixed salary, any variable salary, pensions and other benefits. If the Board also determines that new share-based incentives should be introduced (e.g. employee options), a proposal

DIRECTORS’ REPORT

11

concerning this shall be submitted to the Annual General Meeting for approval.

A description of the guidelines applied in 2009 and the remuneration paid are described in Note 5 on pages 21–24.

Fixed salary

The fixed salary shall take into consideration the individuals’

area of responsibility and experience. This shall be reviewed on an annual basis.

Variable salary

When necessary, the variable salary shall depend on the indi- viduals’ fulfillment of quantitative and qualitative goals. No variable salary shall be paid to the President & CEO. For other senior executives, the variable salary shall amount to not more than 25 percent of fixed salary, whereby the highest level should be based on such factors as the position held by the specific individual.

Pension

Pension benefits shall comprise defined-contribution schemes.

The pension premium shall correspond to not less than that applicable for the ITP plan or not more than 25 percent of fixed salary.

Severance pay, etc

Senior executives shall observe a termination period of not more than 12 months. No severance pay will be issued.

However, the President & CEO shall be entitled to extra remuneration corresponding to four annual salaries in the event of an ownership change that entails that the company in its entirety is acquired or taken over by another party.

Other benefits

Senior executives may be awarded other customary benefits, such as a company car, company healthcare, etc.

Drafting and approval

The President & CEO’s remuneration shall be drafted and approved by the Board of Directors. Other senior executive’s remuneration shall be drafted by the President & CEO, who shall submit a proposal to the Board for approval. The Board of Directors is entitled to deviate from the above principles if it deems that there are particular grounds for doing so in individual cases.

Earlier adopted remuneration packages

The President & CEO is entitled to extra remuneration such as that referred to above under the heading Severance pay, etc.

In other respects, there are no earlier adopted remuneration packages that have not fallen due for payment. However, the company’s outstanding employee stock options may entail costs for the company (social-security costs) in accordance with the information presented in the Annual Report.

Events after the balance-sheet date

n

Teva acquires marketing rights for laquinimod in the Nordic region and Baltic States

Teva Pharmaceutical Industries Ltd and Active Biotech announced on February 8, 2010 that they had amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared with the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.

n

Exploratory data presented for Active Biotech’s ANYARA project

On February 10, Active Biotech presented results from exploratory preclinical studies at the Keystone Symposia

”Molecular and Cellular Biology of Immune Escape in Cancer” held in Keystone, Colorado, USA, February 7–12.

The results of the study demonstrate that TTS therapy can be further enhanced by specifically modulating the immune response in this experimental model.

n

Directed share issue

On April 1, 2010, the Board of Directors – pursuant to the authorization given by the 2009 AGM – resolved to implement a directed share issue comprising 1,418,000 shares placed in funds managed by Sectoral Asset Management. The shares were issued at a subscription

price of SEK 105 per share, corresponding to issue proceeds of approximately SEK 149 million.

Outlook for 2010

Against the background of the continued positive develop- ment of the project portfolio, the Board of Directors has determined that available liquidity, revenues from existing and anticipated partnership agreements and liquidity from the directed share issue implemented by the Board totaling approximately SEK 149 million will provide sufficient financial resources to finance the company’s operations until the first half of 2011. Since the timing for the signing of additional partnership agreements and the receipt of milestone payments from existing agreements is uncertain, no earnings forecast is being issued for fiscal year 2010.

DIRECTORS’ REPORT

12

DIRECTORS’ REPORT

Proposed treatment of loss

The following amount stated in SEK is at the disposal of the Annual General Meeting Share premium reserve 339,714,542

Accumulated loss -341,914,058

Loss for the year -16,334,903

Total 18,534,419

The Board of Directors proposes that the above loss totaling SEK 18,534,419 at the disposal of the Annual General Meeting be carried forward to a new account.

Approval and adoption

The Annual Report and the consolidated financial statements were approved for issue on April 1, 2010. The consolidated income statement, statement of comprehensive income and statement of financial position and the Parent Company’s income statement and balance sheet will be subject for adoption by the Annual General Meeting on May 6, 2010.

Statement by the Board of Directors

The Board of Directors and the President & CEO affirm that the Annual Report was prepared in accordance with gene- rally accepted accounting principles in Sweden and the consolidated accounts were prepared in accordance with the inter- national accounting standards referred to in regulation (EC) No. 1606/2002 of the European Parliament and the Council dated July 19, 2002 governing the application of international accounting standards. The annual accounts and the conso- lidated accounts provide a true and fair view of the Group’s and Parent Company’s financial position and results of opera- tions. The Directors’ Report for the Group and the Parent Company provides a true and fair view of the Group’s and the Parent Company’s operations, position and results, and describes significant risks and uncertainty factors that the Parent Company and Group companies face.

Lund, April 1, 2010

The Board of Directors of Active Biotech AB (publ)

We submitted our Audit Report on April 1, 2010.

KPMG AB

DAVID OLOW Authorized Public Accountant MATS ARNHöG

Chairman

PETER SJöSTRAND PETER STRöM TOMAS NICOLIN

KARIN HALLBECK ANETTE SUNDSTEDT

TOMAS LEANDERSON President & CEO

KLAS KäRRE MAGNHILD SANDBERG-WOLLHEIM

Consolidated income statement

JANUARY 1 – DECEMBER 31

SEK thousands Note 2009 2008

Net sales 2 10 772 53 456

Administrative expenses 3,4 -18 300 -30 658

Research and development expenses 3 -212 046 -207 399

Operating loss 5 -219 574 -184 601

Financial income 6 301 10 159

Financial expenses -10 704 -6 182

Net financial income/expense 6 -4 403 3 977

Loss before tax -223 977 -180 624

Tax 7 - -962

Loss for the year -223 977 -181 586

Loss for the year attributable to:

Parent Company’s shareholders -223 977 -181 586

Minority interests – –

Earnings per share 11

before dilution (SEK) -3,81 -3,66

after dilution (SEK) -3,81 -3,66

Statement of consolidated comprehensive income

JANUARY 1 – DECEMBER 31

SEK thousands Note 2009 2008

Loss for the year -223 977 -181 586

Other comprehensive income

Change in the revaluation reserve -1 314 -1 317

Change in the translation reserve – -639

Tax attributable to other comprehensive income 346 1 328 Total other comprehensive loss for the year -968 -628 Total comprehensive loss for the year -224 945 -182 214 Total other comprehensive loss for the year attributable to:

Parent Company’s shareholders -224 945 -182 214

Minority interests _ _

Consolidated statement of cash flows

JANUARY 1 – DECEMBER 31

SEK thousands Note 19 2009 2008

Operating activities

Loss before tax -223 977 -180 624

Adjustments for non-cash items 9 603 5 351 Cash flow from operating activities

before changes in working capital -214 374 -175 273 Cash flow from changes in working capital

Increase(-)/Reduction(+) in operating receivables -13 816 8 683 Increase(+)/Reduction(-) in operating liabilities 3 418 7 127 Cash flow from operating activities -224 772 -159 463 Investing activities

Acquisition of tangible fixed assets -72 -2 855

Reduction in financial fixed assets - 9 816

Cash flow from investing activities -72 6 961

Financing activities

New share issue 256 208 157 668

Issue expenses -7 200 - 3 816

Borrowings - 3500

Amortization of loan -5 191 -3 784

Amortization of leasing liabilities -1 679 -938

Cash flow from financing activities 242 138 152 630

Cash flow for the year 17 294 128

Cash and cash equivalents, January 1 138 741 138 613 CASH AND CASH EQUIVALENTS AT YEAR-END 156 035 138 741

Consolidated statement of financial position

AT DECEMBER 31

SEK thousands Note 2009 2008

ASSETS

Land and buildings 8 309 434 316 613

Equipment, tools, fixtures and fittings 8 9 558 7 939

Long-term receivables 1 1

Total fixed assets 318 993 324 553

Accounts receivable 547 1 671

Tax receivables 3 882 3 882

Other receivables 7 562 1 120

Prepaid expenses and accrued income 9 11 479 2 981

Cash and cash equivalents 19 156 035 138 741

Total current assets 179 505 148 395

TOTAL ASSETS 498 498 472 948

AT DECEMBER 31

SEK thousands Note 2009 2008

SHAREHOLDERS’ EQUITY

Share capital 241 435 193 148

Other capital contributed 2 272 909 2 072 188

Reserves 40 730 41 698

Loss carryforwards including loss for the year -2 366 433 -2 143 424

Total shareholders’ equity 10 188 641 163 610

LIABILITIES

Liabilities to credit institutions 12 241 068 246 726 Long-term interest-bearing liabilities 12 6 888 5 000

Total long-term liabilities 247 956 251 726

Short-term interest-bearing liabilities 12 7 523 6 652

Accounts payable 13 325 16 213

Tax liabilities 251 460

Other liabilities 13 12 999 2 797

Accrued expenses and deferred income 14 27 803 31 490

Total short-term liabilities 61 901 57 612

TOTAL LIABILITIES 309 856 309 338

TOTAL SHAREHOLDERS’ EQUITY AND LIABILITIES 498 498 472 948

For information pertaining to pledged assets and contingent liabilities, see Note 17.

CONSOLIDATED INCOME STATEMENT • CONSOLIDATED STATEMENT OF CASH FLOWS • STATEMENT OF CONSOLIDATED COMPREHENSIVE INCOME • CONSOLIDATED STATEMENT OF FINANCIAL POSITION

14

Profit/loss brought

Other forward incl. Total

Share capital Translation Revaluation profit/loss shareholders’

SEK thousands Note 10 capital contributions reserve reserve for the year equity

Opening shareholders’ equity, January 1, 2008 178 290 1 933 194 639 41 687 -1 964 240 189 570

Total comprehensive income/loss for the year – – -639 11 -181 586 -182 214

Transfer to revaluation reserve – – – – 949 949

New share issue 14 858 138 994 – – – 153 852

Equity-settled share-based

payments, IFRS 2 – – – – 1 453 1 453

Closing shareholders’ equity, December 31, 2008 193 148 2 072 188 – 41 698 -2 143 424 163 610

Opening shareholders’ equity, January 1, 2009 193 148 2 072 188 – 41 698 -2 143 424 163 610

Total comprehensive loss for the year – – – -968 -223 977 -224 945

Transfer to revaluation reserve – – – – 968 968

New share issue 48 287 200 721 – – – 249 008

Closing shareholders’ equity, December 31, 2009 241 435 2 272 909 – 40 730 -2 366 433 188 641

Statement of changes in consolidated equity

Parent Company income statement

JANUARY 1 – DECEMBER 31

SEK thousands Note 2009 2008

Net sales 2 3 500 46 354

Administrative expenses 3,4 -22 157 -33 225

Operating profit/loss 5 -18 657 13 129

Profit/loss from financial items:

Profit/loss from participations in

Group companies 6 - 37 635

Profit from other securities

and receivables that are fixed assets 6 - 7 363 Interest income and similar items 6 2 327 5 508

Interest expense and similar items 6 -5 -3

Profit/loss after financial items -16 335 63 632

Profit/loss before tax -16 335 63 632

Tax 7 - –

Profit/loss for the year -16 335 63 632

Cash-flow statement for the Parent Company

JANUARY 1 – DECEMBER 31

SEK thousands Note 19 2009 2008

Operating activities

Profit/loss after financial items -16 335 63 632

Adjustments for non-cash items - -43 541

Cash flow from operating activities

before changes in working capital -16 335 20 091 Cash flow from changes in working capital

Increase(-)/Reduction(+) in operating receivables -6 665 8 625 Increase(+)/Reduction(-) in operating liabilities -8 474 -3 616 Cash flow from operating activities -31 474 25 100 Investing activities

Reduction in financial fixed assets - 9 816

Cash flow from investing activities - 9 816

Financing activities

New share issue 256 208 157 667

Issue expenses -7 200 -3 815

Group contributions paid -205 000 -180 000

Cash flow from financing activities 44 008 -26 148

Cash flow for the year 12 534 8 768

Cash and cash equivalents, January 1 131 625 122 857 CASH AND CASH EQUIVALENTS AT YEAR-END 144 159 131 625

STATEMENT OF CHANGES IN CONSOLIDATED EQUITY • PARENT COMPANY INCOME STATEMENT • CASH-FLOW STATEMENT FOR THE PARENT COMPANY